Wesana Health Holdings Inc. (WSNAF)
| Previous Close | 0.1300 |
| Open | 0.1370 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.1370 - 0.1636 |
| 52 Week Range | 0.1100 - 3.9970 |
| Volume | |
| Avg. Volume | 29,032 |
| Market Cap | 3.474M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2710 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Fresh New Market Movers: Today’s Top Stock Picks for New & Trending Opportunities
Fresh New Market Movers: Today's Top Stock Picks for New & Trending OpportunitiesVANCOUVER, BC / ACCESSWIRE / June 15, 2022 / Investors want insight. Welcome to the Market Movers Newsletter where we have created a snapshot of new and trending companies that we think investors will want to know about.
- GlobeNewswire
Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies
His talk will kick-off the daylong biotechnology conference on cutting-edge therapiesCHICAGO and TORONTO, June 08, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to confirm CEO Daniel Carcillo will be keynoting the upcoming Charles River Symposium, “Re-imagining Substance Abuse, Addiction, and Me
- GlobeNewswire
Wesana Announces First Quarter 2022 Financial Results
CHICAGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, has today announced its first quarter 2022 financial results. Q1 2022 Highlights Delivered findings indicating psilocybin potentiates impact of anti-depressantReceived positive feedback from pre-Investigational New Drug (“IND”) meet
